Adjuvant therapy for HER2+ breast cancer: Practice, perception, and toxicity

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 713-721

  Rocque, Gabrielle ^a,b   Onitilo, Adedayo ^c   Engel, Jessica ^c   Pettke, Erica ^b   Boshoven, Alice ^b   Kim, Kyungmann ^a,b   Rishi, Shailly ^c   Waack, Bonnie ^c   Wisinski, Kari B ^a,b   Tevaarwerk, Amye ^a,b   Burkard, Mark E ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MARSHFIELD CLINIC   (United States)

Author keywords

Cardiotoxicity; Chemotherapy; ErbB2; Myelosuppression; Neutropenic fever; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; TRASTUZUMAB;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DRUG ERUPTION; DRUG PREFERENCE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY CANCER; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; ONCOLOGIST; PATIENT ATTITUDE; PHYSICIAN; PRIORITY JOURNAL; RHEUMATIC DISEASE; SIDE EFFECT; THROMBOCYTOPENIA; UNITED STATES; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MEDICAL ONCOLOGY; MIDDLE AGED; PHYSICIAN'S ROLE; RECEPTOR, ERBB-2; TIME FACTORS;

EID: 84856226246     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1862-y     Document Type: Article

References (23)

1. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 1659 1672 10.1056/NEJMoa052306 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
2. EH Romond EA Perez J Bryant VJ Suman CE Geyer Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 1673 1684 10.1056/NEJMoa052122 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
3. D Slamon W Eiermann N Robert T Pienkowski M Martin M Press J Mackey J Glaspy A Chan M Pawlicki T Pinter V Valero M Liu G Sauter G Von Minckwitz F Visco V Bee M Buyse B Bendahmane I Tabah-Fisch MA Lindsay A Riva J Crown 2011 Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 1273 1283 21991949 10.1056/NEJMoa0910383 1:CAS:528:DC%2BC3MXht12mtLvN
4. EA Perez EH Romond VJ Suman JH Jeong NE Davidson CE Geyer Jr S Martino EP Mamounas PA Kaufman N Wolmark 2011 Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 J Clin Oncol 29 25 3366 3373 10.1200/JCO.2011.35.0868 21768458 10.1200/JCO.2011.35.0868 1:CAS:528:DC%2BC3MXhtlWisLbN
5. M Procter TM Suter E de Azambuja U Dafni V van Dooren S Muehlbauer MA Climent E Rechberger WT Liu M Toi RC Coombes D Dodwell O Pagani J Madrid M Hall SC Chen C Focan M Muschol DJ van Veldhuisen MJ Piccart-Gebhart 2010 Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial J Clin Oncol 28 21 3422 3428 10.1200/JCO.2009.26.0463 20530280 10.1200/JCO.2009.26.0463
6. SD Russell KL Blackwell J Lawrence JE Pippen Jr MT Roe F Wood V Paton E Holmgren KW Mahaffey 2010 Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials J Clin Oncol 28 21 3416 3421 10.1200/JCO.2009.23. 6950 20530275 10.1200/JCO.2009.23.6950 1:CAS:528:DC%2BC3cXhtVGis7fN
7. PG Morris CA Hudis 2010 Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J Clin Oncol 28 21 3407 3410 10.1200/JCO.2009.26.0125 20530269 10.1200/JCO.2009.26.0125 1:CAS:528:DC%2BC3cXhtVGis7bE
8. V Valero J Forbes MD Pegram T Pienkowski W Eiermann G von Minckwitz H Roche M Martin J Crown JR Mackey P Fumoleau J Rolski Z Mrsic-Krmpotic A Jagiello-Gruszfeld A Riva M Buyse H Taupin G Sauter MF Press DJ Slamon 2010 Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens J Clin Oncol 29 2 149 156 10.1200/JCO.2010.28.6450 21115860 10.1200/JCO.2010.28.6450
9. L Gianni L Norton N Wolmark TM Suter G Bonadonna GN Hortobagyi 2009 Role of anthracyclines in the treatment of early breast cancer J Clin Oncol 27 28 4798 4808 10.1200/JCO.2008.21.4791 19687331 10.1200/JCO.2008.21.4791
10. MF Press G Sauter M Buyse L Bernstein R Guzman A Santiago IE Villalobos W Eiermann T Pienkowski M Martin N Robert J Crown V Bee H Taupin KJ Flom I Tabah-Fisch G Pauletti MA Lindsay A Riva DJ Slamon 2011 Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy J Clin Oncol 29 7 859 867 10.1200/JCO.2009.27.5644 21189395 10.1200/JCO.2009.27.5644 1:CAS:528: DC%2BC3MXktlelsLY%3D
11. Herceptin (package insert) (2010) Genentech, Inc., South San Francisco, CA. http://www.gene.com/gene/products/information/pdf/herceptin-prescribing.pdf
12. AM Gonzalez-Angulo JK Litton KR Broglio F Meric-Bernstam R Rakkhit F Cardoso F Peintinger EO Hanrahan A Sahin M Guray D Larsimont F Feoli H Stranzl TA Buchholz V Valero R Theriault M Piccart-Gebhart PM Ravdin DA Berry GN Hortobagyi 2009 High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27 34 5700 5706 10.1200/JCO.2009.23.2025 19884543 10.1200/JCO.2009.23.2025
13. McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer. doi: 10.1002/cncr.26171
14. ML Citron DA Berry C Cirrincione C Hudis EP Winer WJ Gradishar NE Davidson S Martino R Livingston JN Ingle EA Perez J Carpenter D Hurd JF Holland BL Smith CI Sartor EH Leung J Abrams RL Schilsky HB Muss L Norton 2003 Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 8 1431 1439 10.1200/JCO.2003.09.081 12668651 10.1200/JCO.2003.09.081 1:CAS:528: DC%2BD2cXptlCks7s%3D (Pubitemid 46594092)
15. C Dang M Fornier S Sugarman T Troso-Sandoval D Lake G D'Andrea A Seidman N Sklarin M Dickler V Currie T Gilewski ME Moynahan P Drullinsky M Robson C Wasserheit-Leiblich N Mills R Steingart K Panageas L Norton C Hudis 2008 The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer J Clin Oncol 26 8 1216 1222 10.1200/JCO.2007.12.0733 18323546 10.1200/JCO.2007.12.0733 1:CAS:528:DC%2BD1cXksVehu70%3D
16. PG Morris M Dickler HL McArthur T Traina S Sugarman N Lin B Moy S Come L Godfrey B Nulsen C Chen R Steingart H Rugo L Norton E Winer CA Hudis CT Dang 2009 Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction J Clin Oncol 27 36 6117 6123 10.1200/JCO.2008.20.2952 19901120 10.1200/JCO.2008.20.2952 1:CAS:528:DC%2BC3cXht1agsLY%3D
17. J Baselga X Carbonell NJ Castaneda-Soto M Clemens M Green V Harvey S Morales C Barton P Ghahramani 2005 Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule J Clin Oncol 23 10 2162 2171 10.1200/JCO.2005.01.014 15800309 10.1200/JCO.2005.01.014 1:CAS:528:DC%2BD2MXjsVyiu7w%3D (Pubitemid 46218708)
18. M Subar W Lin W Chen DG Pittman 2011 Lack of uniformity in cardiac assessment during trastuzumab therapy Breast J 17 4 383 390 10.1111/j.1524-4741. 2011.01101.x 21615821 10.1111/j.1524-4741.2011.01101.x
19. TJ Smith J Khatcheressian GH Lyman H Ozer JO Armitage L Balducci CL Bennett SB Cantor J Crawford SJ Cross G Demetri CE Desch PA Pizzo CA Schiffer L Schwartzberg MR Somerfield G Somlo JC Wade JL Wade RJ Winn AJ Wozniak AC Wolff 2006 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 19 3187 3205 10.1200/JCO.2006.06.4451 16682719 10.1200/JCO.2006.06.4451 1:CAS:528:DC%2BD28XnslKhsLo%3D (Pubitemid 46638957)
20. T Vandenberg J Younus S Al-Khayyat 2010 Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis Curr Oncol 17 2 2 3 20404969 10.3747/co.v17i2.498 1:STN:280: DC%2BC3c3nsVKktQ%3D%3D
21. D Soong R Haj MG Leung R Myers B Higgins J Myers S Rajagopal 2009 High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide J Clin Oncol 27 26 e101 e102 10.1200/JCO.2009.23. 0508 19652050 10.1200/JCO.2009.23.0508
22. Ivy SP, Zweibel J, Mooney M (2010) Follow-up for information letter regarding AUC-based dosing of carboplatin. Public Health Service, Bethesda
23. AH Calvert DR Newell LA Gumbrell S O'Reilly M Burnell FE Boxall ZH Siddik IR Judson ME Gore E Wiltshaw 1989 Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 11 1748 1756 2681557 1:STN:280:DyaK3c%2FjvFCmug%3D%3D (Pubitemid 19272848)